HUE027025T2 - Nem-citotoxikus fehérjekonjugátumok - Google Patents
Nem-citotoxikus fehérjekonjugátumok Download PDFInfo
- Publication number
- HUE027025T2 HUE027025T2 HUE10166556A HUE10166556A HUE027025T2 HU E027025 T2 HUE027025 T2 HU E027025T2 HU E10166556 A HUE10166556 A HU E10166556A HU E10166556 A HUE10166556 A HU E10166556A HU E027025 T2 HUE027025 T2 HU E027025T2
- Authority
- HU
- Hungary
- Prior art keywords
- asn
- leu
- lys
- ile
- glu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Claims (12)
- Szabadalmi igénypontok I. igylánoá pelipeptid fiizíós hfeérje, amely tarfefe3^ a, egy nemHÚtotoxikas proíeází vagy annak egy ffegmertséfe amäy protéáz vagy profeáziragmens képes egy noeí eeptfv érző afférén«. egy féM^lfénék has kásása: b, egy célzó emportât, amty képes a «oefeeptív szenzoros «formen kötőhelyhez kötődni, amely kötőhely képes endocltözison keresztőltnenöi, hagy egy noclcepil v érző affemssben taláíhatő endószőmába kerüljön be; e, egy proteáz hasítási helyek amely helyen a fúziós fehérje hasítható egy proteázzal, ahol a proteáz hasítási hely a nem-eítmoxikus proteáz vagy annak egy feagmense és a célzó csoport között helyezkedik el; 1. egy írasszlokációs domént, amely képes a proteázt vagy a proteázfeagpcosí átjuttatni egy eadöSZőmáu belülről az a rtoeicepriv érző afíerats citoszoljába; ahol a célzó csoport a pröiéáz; hasítási hely és a imnszl okáclós dómén között helyezkedik el, és ahol a proteáz! (vagy ffaginenséí} és a transziokációs dotnént legfeljebb ÍÖO aminosav választja el egymástól.
- 2. Az I, igénypont szerimi íhzíós fehérje, ahol a célzó csoportot és a profeáz hasítási helyet legfeljebb lö aminosav, előnyösen legfeljebb 5 aminosav, és előnyösebben legfeljebb nulla aminosav választja el egymástól.
- 3. A háfméty előző igénypont szerinti fúziós fehérje, ahol a nem-citofoxikus proteàz Clostridium neumtoxin L-láne vagy egy IgA-ptöíeáz,
- 4. A bármély előző ígénypóife szerinti fúziós fehérje, ahol a ímnsziokáetöá dómén a Clostridium netsretoxin 1-1¾ döméiyé, §. A bármely előző Igénypont szerinti fúziós fehérje, abet á célzó csoport legfeljebb M amínosavat, előiryösén legfeljebb 40 afelhosáy&í, előnyösebben legfeljebb |Ö amtnosavat és legelőnyösebbén legfeljebb 2ö amíhosávai fertalmaz, é. Az 1-5. igénypontok bármelyike szerinti fúziós feifeí je, iából a eélzö csopórtr (i) opioid; (it) egy nocieepttv érző alferensen jelen lévő receptor agonísíája, előnyösen ahol a célzó csoport egy primer nocíoeptlv érző afferensen jelen lévő receptor agonisiája; Cm) az OitLi receptorhoz kötődik, előnyösen ahol a sélző csopeát specifikusan kötődik az ORti receptorhoz, előnyösebben ahol a célzó csoport az ORL* reeéplor ágóftislája·
- 7. A ő. igénypont szerinti fúziós fehérje, aboi a Célzó'Csoport legalább 70% ámioosavszekvencia-azonősságot mutat a SEQ 10 No. 38 szerinti szekvenciával vagy égy frápnéhsévél, vagy ahol a célzó csoport legalább 86% amínosavszekvenela-szonosságoí feulât a &EQ .10 Mik 38 szeritől szekvenciával vagy egy tragmensével, vagy almi 3 célzó csoport legalább 90% atninosávszekvenda-azonosságoí mutat á |ËQ ID No. 38 szerinti szekvenciával vagy egy Éagrnessével, vagy ahol a célzó csoport legalább 955« amloossyszekveneiá-azonosságot mutat a SEQ ID No, 38 szerinti szekvenciával vágy égy llágmensévék vagy aboi a eélzó csoport g SEQ K>!IÍáiJl szerinti szék verteié vágy egy ifagmense, vagyakéi a. Célzó csoport a SEQ ID jsioi; 40,42,44* 4Ő* 48 vagy Sö jeli szekvencia, vagy alól a célzó csoport noeícepttn. &. Az |·>5> igénypontok bármelyike szerinti fúziós fehérje, «tó a célzó csoport a következőkből álló csoportból van kiválasztva: noéicepiln, {jhsndorßn* eodomorSn^l/^dboimlia-S, dinorím, mm-enkeidm, feu~ enkefaim, gaianio és PAR-2 pepiid.
- 9. Bármely előző igénypont szerinti fSæsàî fehérje; ahoi a főziós fehérje tartalmaz egy iisztllasí címkét; előnyősén ahol a fúziós fehérje tartalmaz egy tisztítási címkét, ameiy * fúziós fehérje NrtmmHáitsán és/vagy ©terminálisán van jeles; előnyösebbért ahoi a tisztítási címke egy pepiid távköz molekulán keresztíd kapcsolódik a fözios fehérjéhez.
- 10. Bármely előző Igénypont szerinti fózios fehérje, ahol a transzíokációs domént egy pepiid távkőz molekula válaézíja pl a célsó esopörttől.
- 11. Niikleiosav-szokVéneia, elő# fénypont ps^Éift^líipephjdÍ föziós fehérjét kódol,
- 12. DNS-vektor, amely tartalmaz egy proorótert, egy I I. igétsyponí szerinti rsukleinsav-szekveaelát. ahol a DNS-szekvencia a pomőtertöí downstream heiyésáledík el, és egy ténnináior szekvencia találhat# a DiyS'kotistmkcióíói downstream irányban.
- 13. Eljárás egy Ι4Θ, igénypontok bármelyike szerinti egyiánoá, polipeptid Hzlos fehérje előállítására, melynek során égy iil> igénylőm szerinti mtkMhsavat vagy 12. igénypont szerinti DláS-vekíort expresszákatunk gazdasejtben.
- 14. Eljárás Uemfeitótoxikus szer előállítására, amelynek során: a. egy I* I®. igénypont szerinti egyláucó, pokpeptM ÍSziós -fehérjét érintkezésbe hozunk, egy proteázzal, amely képes a proteáz hasítási hely elhasiíására; h. elh&siíjnk a proteáz hasítási helyet; és ezáltal egy kétláncb fizips fehérjéi Itöznuk ft|,
- 15. Nenvciíototdkus ppHpepbd, amely a 14, igénypont szerintieljárással eÄlihhatö, aból a jsolipeptid kétláncá polipeptid, és alsói; a. az első lánc tartalmazza a nem-etetoxikps proteázt vagy egy frsgmensét, amely proteáz vagy prptéázlragmens képes egy nociceptiv érző aftereas ezocltdíjküs liizlós apparátusa egy fehérjéjének hasítására; b. a második lánc tartalmazza a célzó csoportot és a iransklokáeiós dómén·, amely képes a proteázt vagy a proteázhngmesst kimarni égy endoszómán belölhőí az endoszomáils membránon kérésztől a odeieeptív érző aíférens eifoszoijábít; és az első és második:lábPófe disznllidkőíéssei kapcsolódnak egymáshoz. lő. Az 14Ö. igéhypöntdk bártneiylke szerinti fözips fehérje vagy a 15. Igénypont szerinti polípeplkl: alkalmazása égy, fájáalbm kezéléséfe, megelőzésére vagy enyhttéséfé Szolgáló gyógyszer előállítására; előnyösen ahol a lijáalőm krónikus fájdalom. |7> Az i-íö, igénypontok bármelyike szerinti fúziós fehérje vagy a 15. Igénypont szerinti polipeptid fájdalom kezeléséré. megelőzésére vagy enyhítésére szolgáló gyógyszer előállításában tlftéhő áikakmtzákrá; előnyösen ahol aflpialmp krónikus fájdalom.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0426394A GB0426394D0 (en) | 2004-12-01 | 2004-12-01 | Fusion proteins |
GB0504964A GB0504964D0 (en) | 2004-12-01 | 2005-03-10 | Fusion proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE027025T2 true HUE027025T2 (hu) | 2016-08-29 |
Family
ID=34043886
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE10166556A HUE027025T2 (hu) | 2004-12-01 | 2005-12-01 | Nem-citotoxikus fehérjekonjugátumok |
HUE10184114A HUE025964T2 (hu) | 2004-12-01 | 2005-12-01 | Nem-citotoxikus fehérjekonjugátumok |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE10184114A HUE025964T2 (hu) | 2004-12-01 | 2005-12-01 | Nem-citotoxikus fehérjekonjugátumok |
Country Status (13)
Country | Link |
---|---|
US (5) | US8067200B2 (hu) |
EP (4) | EP2204182B1 (hu) |
JP (7) | JP5174463B2 (hu) |
AT (1) | ATE488245T1 (hu) |
CY (2) | CY1111324T1 (hu) |
DE (1) | DE602005024857D1 (hu) |
DK (6) | DK2366399T3 (hu) |
ES (6) | ES2356179T3 (hu) |
GB (3) | GB0426394D0 (hu) |
HU (2) | HUE027025T2 (hu) |
PL (3) | PL2292249T3 (hu) |
PT (5) | PT1877073E (hu) |
SI (2) | SI1830872T1 (hu) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
WO2001014570A1 (en) * | 1999-08-25 | 2001-03-01 | Allergan Sales, Inc. | Activatable recombinant neurotoxins |
WO2004043405A2 (en) | 2002-11-12 | 2004-05-27 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
JP4994241B2 (ja) * | 2004-11-22 | 2012-08-08 | ニューヨーク・ユニバーシティ | 遺伝子操作されたクロストリジウム遺伝子、操作された遺伝子によりコードされるタンパク質、およびその使用 |
GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
US8399400B2 (en) * | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
US8512984B2 (en) * | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US8778634B2 (en) | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
AR060187A1 (es) * | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Composicion inmunogenica |
GB0610867D0 (en) * | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
US10792344B2 (en) | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
KR101604515B1 (ko) * | 2008-03-14 | 2016-03-17 | 알러간, 인코포레이티드 | 면역-기반 보툴리눔 독소 세로타입 a 활성 검정 |
SI3031825T1 (sl) | 2008-03-14 | 2019-12-31 | Allergan, Inc. | Preizkusi aktivnosti serotipa A botulin toksina na podlagi imunosti |
AU2009259034B2 (en) | 2008-06-12 | 2013-10-31 | Ipsen Bioinnovation Limited | Suppression of cancers |
US20110171191A1 (en) * | 2008-06-12 | 2011-07-14 | Syntaxin Limited | Suppression of neuroendocrine diseases |
KR20110031393A (ko) | 2008-07-21 | 2011-03-25 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물 |
GB0820970D0 (en) * | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
WO2010090677A1 (en) | 2008-12-10 | 2010-08-12 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
KR101923847B1 (ko) | 2009-03-13 | 2018-11-29 | 알러간, 인코포레이티드 | 면역 기반 재표적화된 엔도펩티다제 활성 검정 |
US8198229B2 (en) * | 2009-05-29 | 2012-06-12 | Allergan, Inc. | Methods of treating urogenital-neurological disorders using galanin retargeted endopepidases |
AU2010353292A1 (en) | 2009-12-16 | 2012-07-12 | Allergan, Inc. | Modified Clostridial toxins comprising an integrated protease cleavage site-binding domain |
EP2528941A4 (en) * | 2010-01-25 | 2013-05-29 | Univ New York | RECOMBINANT BOTULINUM NEUROTOXIN DERIVATIVES MODIFIED FOR TRAFFIC STUDIES AND NEURONAL DELIVERY |
WO2011091370A1 (en) | 2010-01-25 | 2011-07-28 | Allergan, Inc. | Methods of intracellular conversion of single-chain proteins into their di-chain form |
ES2600463T3 (es) | 2010-05-20 | 2017-02-09 | Allergan, Inc. | Toxinas clostridiales degradables |
AU2011315962B2 (en) | 2010-10-14 | 2016-06-02 | Allergan, Inc. | Targeted delivery of Targeted Exocytosis Modulators to the sphenopalatine ganglion for treatment of headache disorders |
WO2012112420A1 (en) | 2011-02-14 | 2012-08-23 | Allergan, Inc. | Treatments using psma ligand endopeptidases |
US20120244188A1 (en) | 2011-03-25 | 2012-09-27 | Allergan, Inc. | Treatment of Sensory Disturbance Disorders |
US20120251574A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions |
US20120251573A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Neuroendocrine Disorders |
US20120251575A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Involuntary Movement Disorders |
US20120251515A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Cosmesis Disorders |
US20120258132A1 (en) | 2011-03-29 | 2012-10-11 | Allergan, Inc. | Vagal Nerve-Based Disorders |
US20120251518A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Sexual Dysfunction Disorders |
US20120251519A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Smooth Muscle Disorders |
US8697090B2 (en) | 2011-05-05 | 2014-04-15 | Allergan, Inc. | Method of treating persistent genital arousal disorder with a neurotoxin |
GB201108108D0 (en) * | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
WO2012174123A1 (en) | 2011-06-13 | 2012-12-20 | Allergan, Inc. | Treatment of psychological trauma |
CA2841139C (en) | 2011-07-08 | 2017-01-17 | Allergan, Inc. | Method for treatment of autonomic nervous system disorders |
US8992941B2 (en) | 2011-07-08 | 2015-03-31 | Allergan, Inc. | Method for treatment of esophageal spasm |
CN103813802A (zh) | 2011-07-14 | 2014-05-21 | 阿勒根公司 | 用于治疗与性活动相关的失禁的方法 |
US20130171122A1 (en) | 2011-12-29 | 2013-07-04 | Allergan, Inc. | Endopeptidase and neurotoxin combination treatment of bladder disorders |
EP2798077A2 (en) | 2011-12-31 | 2014-11-05 | Allergan, Inc. | Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A |
US20140056870A1 (en) | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
CA2880897C (en) * | 2012-11-21 | 2020-01-14 | Syntaxin Limited | Methods for the manufacture of proteolytically processed polypeptides |
WO2014100019A1 (en) | 2012-12-18 | 2014-06-26 | Allergan, Inc. | Prophylactic treatment of herpes recurrence |
JP2016513082A (ja) | 2013-01-28 | 2016-05-12 | ニューヨーク・ユニバーシティ | 無毒性神経毒誘導体を用いる治療方法 |
US11897921B2 (en) | 2014-12-09 | 2024-02-13 | New York University | Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain |
CN109803673A (zh) | 2016-09-13 | 2019-05-24 | 阿勒根公司 | 非蛋白质梭菌毒素组合物 |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
KR102483296B1 (ko) | 2017-12-26 | 2022-12-30 | 가부시키가이샤 굿맨 | 지혈 기구 |
WO2019147478A2 (en) * | 2018-01-18 | 2019-08-01 | California Institute Of Technology | Programmable protein circuits in living cells |
US11965191B2 (en) | 2018-01-18 | 2024-04-23 | California Institute Of Technology | Programmable protein circuits in living cells |
DE102018114028A1 (de) * | 2018-06-12 | 2019-12-12 | Bundesrepublik Deutschland (Robert Koch-Institut) | Probenpräparation für proteomische Untersuchungen |
US11453893B2 (en) | 2018-08-30 | 2022-09-27 | California Institute Of Technology | RNA-based delivery systems with levels of control |
EP3844180A4 (en) | 2018-08-31 | 2022-07-20 | California Institute of Technology | SYNTHETIC PROTEIN CIRCUITRY FOR DETECTING SIGNAL TRANSDUCER ACTIVITY |
WO2020146627A1 (en) | 2019-01-10 | 2020-07-16 | California Institute Of Technology | A synthetic system for tunable thresholding of protein signals |
GB201900621D0 (en) * | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
WO2022152939A1 (en) | 2021-01-18 | 2022-07-21 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5668255A (en) * | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
CA2071969A1 (en) * | 1989-12-22 | 1991-06-23 | John R. Murphy | Hybrid molecules having translocation region and cell-binding region |
US5200722A (en) | 1991-11-27 | 1993-04-06 | United Solar Systems Corporation | Microwave window assembly |
AU3658093A (en) | 1992-02-10 | 1993-09-03 | Seragen, Inc. | Desensitization to specific allergens |
GB9305735D0 (en) * | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
JP3570516B2 (ja) | 1993-06-29 | 2004-09-29 | カイロン コーポレイション | 増加した生物学的活性を有する短縮型ケラチノサイト増殖因子(kgf) |
WO1995032222A1 (en) | 1994-05-19 | 1995-11-30 | Monsanto Company | Method for purifying somatotropin monomers |
GB9411138D0 (en) | 1994-06-03 | 1994-07-27 | Microbiological Res Authority | Toxin assay |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
EP0845034B1 (en) | 1995-08-15 | 2003-03-05 | Euroscreen S.A. | peptide having pronociceptive properties |
AU7566396A (en) * | 1995-11-16 | 1997-06-05 | Boehringer Mannheim Gmbh | Process for the preparation of peptides by way of streptavidin fusion proteins |
GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
WO1999003880A1 (en) * | 1997-07-15 | 1999-01-28 | Novo Nordisk A/S | Nociceptin analogues |
GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
CN1241945C (zh) | 1998-05-13 | 2006-02-15 | 拜欧特康生化技术开发和咨询有限公司 | 用于抑制肥大细胞脱粒的杂合蛋白质及其用途 |
DE69910216T2 (de) | 1998-07-22 | 2004-02-19 | Osprey Pharmaceuticals Ltd., Calgary | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung |
US20040071736A1 (en) | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
US8790897B2 (en) | 1998-08-25 | 2014-07-29 | Syntaxin Ltd. | Treatment of mucus hypersecretion |
GB9907429D0 (en) | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
US6776990B2 (en) * | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
US7740868B2 (en) | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
WO2001014570A1 (en) * | 1999-08-25 | 2001-03-01 | Allergan Sales, Inc. | Activatable recombinant neurotoxins |
US20080032931A1 (en) | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
US20090018081A1 (en) | 1999-08-25 | 2009-01-15 | Allergan, Inc. | Activatable clostridial toxins |
GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
US20080038274A1 (en) | 1999-09-23 | 2008-02-14 | Foster Keith A | Inhibition of secretion from non-neuronal cells |
US20030180289A1 (en) | 1999-09-23 | 2003-09-25 | Foster Keith Alan | Inhibition of secretion from non-neuronal cells |
WO2001058936A2 (en) | 1999-12-02 | 2001-08-16 | Microbiological Research Authority | Constructs for delivery of therapeutic agents to neuronal cells |
US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
US7138127B1 (en) | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
WO2002000172A2 (en) | 2000-06-28 | 2002-01-03 | Ira Sanders | Methods for using tetanus toxin for benificial purposes in animals (mammals) |
ITMI20022022A1 (it) * | 2002-09-24 | 2004-03-25 | Girolamo Calo' | Analoghi di nocicettina. |
GB0228723D0 (en) | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
US20040115727A1 (en) | 2002-12-11 | 2004-06-17 | Allergan, Inc., A Corporation | Evolved clostridial toxins with altered protease specificity |
GB0305149D0 (en) | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
GB0321344D0 (en) | 2003-09-11 | 2003-10-15 | Health Prot Agency | Re-targeted toxin conjugates |
US7514088B2 (en) | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
US7892565B2 (en) | 2004-09-01 | 2011-02-22 | Allergan, Inc. | Degradable clostridial toxins |
JP4994241B2 (ja) | 2004-11-22 | 2012-08-08 | ニューヨーク・ユニバーシティ | 遺伝子操作されたクロストリジウム遺伝子、操作された遺伝子によりコードされるタンパク質、およびその使用 |
GB0426397D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
WO2006059093A2 (en) | 2004-12-01 | 2006-06-08 | Health Protection Agency | Fusion proteins |
US8778634B2 (en) * | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US7659092B2 (en) * | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
AU2005311098B2 (en) | 2004-12-01 | 2011-08-11 | Allergan, Inc. | Non-cytotoxic protein conjugates |
GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
JP2010500967A (ja) * | 2006-07-20 | 2010-01-14 | ザ ジェネラル ホスピタル コーポレイション | コンビナトリアルターゲティングを通じたプロトキシンの選択的活性化のための方法、組成物、およびキット |
US20080023928A1 (en) * | 2006-07-25 | 2008-01-31 | Lee Cole | Quad roller skate |
EP2214696A1 (en) * | 2007-10-23 | 2010-08-11 | Allergan, Inc. | Methods of treating chronic neurogenic inflammation using modified clostridial toxins |
BRPI0817775A2 (pt) * | 2007-10-23 | 2015-03-24 | Allergan Inc | Métodos de tratar distúrbios urogenitais-neurológicos usando toxinas clostridiais modificadas |
WO2010085473A1 (en) | 2009-01-20 | 2010-07-29 | Trustees Of Tufts College | Methods for the delivery of toxins or enzymatically active portions thereof |
US20100303757A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases |
US20100303791A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases |
US20100303789A1 (en) | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases |
GB201108108D0 (en) | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
-
2004
- 2004-12-01 GB GB0426394A patent/GB0426394D0/en not_active Ceased
-
2005
- 2005-03-10 GB GB0504966A patent/GB0504966D0/en not_active Ceased
- 2005-03-10 GB GB0504964A patent/GB0504964D0/en not_active Ceased
- 2005-12-01 EP EP20100157432 patent/EP2204182B1/en active Active
- 2005-12-01 DK DK10166556.0T patent/DK2366399T3/en active
- 2005-12-01 AT AT05810103T patent/ATE488245T1/de active
- 2005-12-01 DE DE200560024857 patent/DE602005024857D1/de active Active
- 2005-12-01 SI SI200531230T patent/SI1830872T1/sl unknown
- 2005-12-01 ES ES05810103T patent/ES2356179T3/es active Active
- 2005-12-01 EP EP20100166556 patent/EP2366399B1/en active Active
- 2005-12-01 SI SI200531796T patent/SI1877073T1/sl unknown
- 2005-12-01 ES ES10166556.0T patent/ES2540111T3/es active Active
- 2005-12-01 PT PT58107111T patent/PT1877073E/pt unknown
- 2005-12-01 ES ES10184150.0T patent/ES2547546T3/es active Active
- 2005-12-01 DK DK05810711T patent/DK1877073T3/da active
- 2005-12-01 PL PL10184114T patent/PL2292249T3/pl unknown
- 2005-12-01 JP JP2007543906A patent/JP5174463B2/ja not_active Expired - Fee Related
- 2005-12-01 ES ES10157432T patent/ES2387013T3/es active Active
- 2005-12-01 DK DK10184114.6T patent/DK2292249T3/en active
- 2005-12-01 US US11/792,210 patent/US8067200B2/en active Active
- 2005-12-01 ES ES10184114.6T patent/ES2548329T3/es active Active
- 2005-12-01 DK DK10184150.0T patent/DK2335718T3/en active
- 2005-12-01 PT PT101841146T patent/PT2292249E/pt unknown
- 2005-12-01 PL PL10166556T patent/PL2366399T3/pl unknown
- 2005-12-01 ES ES05810711T patent/ES2431119T3/es active Active
- 2005-12-01 HU HUE10166556A patent/HUE027025T2/hu unknown
- 2005-12-01 DK DK10157432T patent/DK2204182T3/da active
- 2005-12-01 US US11/791,979 patent/US8187834B2/en active Active
- 2005-12-01 PT PT05810103T patent/PT1830872E/pt unknown
- 2005-12-01 PL PL10184150T patent/PL2335718T3/pl unknown
- 2005-12-01 JP JP2007543908A patent/JP5174464B2/ja not_active Expired - Fee Related
- 2005-12-01 PT PT101841500T patent/PT2335718E/pt unknown
- 2005-12-01 PT PT101665560T patent/PT2366399E/pt unknown
- 2005-12-01 EP EP10184114.6A patent/EP2292249B1/en active Active
- 2005-12-01 HU HUE10184114A patent/HUE025964T2/hu unknown
- 2005-12-01 DK DK05810103T patent/DK1830872T3/da active
- 2005-12-01 EP EP10184150.0A patent/EP2335718B1/en active Active
-
2007
- 2007-07-27 US US11/829,118 patent/US7658933B2/en active Active
-
2011
- 2011-02-16 CY CY20111100201T patent/CY1111324T1/el unknown
- 2011-03-28 US US13/072,865 patent/US9139635B2/en active Active
- 2011-09-22 US US13/239,573 patent/US8399401B2/en active Active
- 2011-11-25 JP JP2011258137A patent/JP5536017B2/ja not_active Expired - Fee Related
-
2012
- 2012-10-25 JP JP2012236094A patent/JP5739854B2/ja not_active Expired - Fee Related
-
2013
- 2013-12-20 CY CY20131101153T patent/CY1114954T1/el unknown
-
2014
- 2014-01-29 JP JP2014014941A patent/JP6027035B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-18 JP JP2016100002A patent/JP2016147907A/ja active Pending
-
2019
- 2019-04-03 JP JP2019071418A patent/JP2019131585A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2366399T3 (en) | Non-cytotoxic protein conjugates | |
CA2595115C (en) | Fusion proteins for treating, preventing or ameliorating pain | |
AU2005311098B2 (en) | Non-cytotoxic protein conjugates | |
US7659092B2 (en) | Fusion proteins | |
AU2012203056B2 (en) | Fusion proteins | |
AU2011244911B2 (en) | Non-cytotoxic protein conjugates |